Alendronate News
Helen Hayes Hospital seeks best treatments for osteoporosis
Not long ago, women who found out that they had osteoporosis were told there was little they could do but drink milk, take calcium supplements and try to guard against bone fractures that might eventually cripple them.
Rosenbaum Faria LLP Prepares to Take on Merck on Behalf of Patients Who Suffered Dead Jaw From Fosamax
In response to the FDA warnings and reports from more than 2,400 patients that Fosamax and Fosamax Plus D are linked to Dead Jaw Disease, Rosenbaum Faria LLP, a Manhattan-based lawfirm, intends to proceed against pharmaceutical...
Higher Persistency Rates Seen With FOSAMAX® Once Weekly Therapies Compared To Other Weekly And Monthly Oral Bisphosphonates
Higher persistency rates were seen among osteoporosis patients taking FOSAMAX® Once Weekly (alendronate) therapies than were seen among patients taking ibandronate once monthly or once weekly risedronate therapies, according to...
Encouraging Sign For Long-term Safety Of Bisphosphonates
Skeletal microdamage resulting from bisphosphonate treatment may be maximal during the first year of treatment, and not continue to accumulate with longer periods of treatment, according to new research being presented today at...
Merck, Teva Drop Trial Plans In Bone-Drug Patent Fight
A long-scheduled showdown between Merck & Co. (MRK) and Teva Pharmaceuticals USA Inc. over rights to once-weekly formulations of osteoporosis treatments has been taken off the calendar of a federal court.